Alamar Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary

What happened

Alamar Biosciences reported an adjusted loss of 19 cents per share for the quarter ended September 30, compared with analysts’ average expected loss of 21 cents. Revenue was $33.55 million, above the $30.19 million analysts expected, while the company reported a $13.34 million quarterly loss.

Confirmed

Global impact / market context

Revenue exceeding expectations suggests sales were stronger than analysts forecast, while the smaller adjusted loss per share indicates the reported result was less negative than expected. However, the company still recorded a substantial quarterly loss, so continued costs and progress toward improving profitability remain important to investors.

Analyst inference

Analysts’ average rating was “buy,” with four strong-buy or buy recommendations and one hold; the median 12-month share-price target was $33.00 versus a last close of $28.94. The shares had fallen 15.1% during the quarter, despite the results exceeding average forecasts.

Confirmed

What to watch

1. Watch future revenue reports against analyst expectations: sustained sales growth could support operating performance, while slower growth would make it harder to cover the costs reflected in quarterly losses. Analyst inference
2. Track whether the reported loss narrows in coming quarters; reduced losses would indicate progress toward profitability, while persistent or larger losses could increase the company’s need for cash. Analyst inference
3. Analysts’ current average rating is “buy,” and their median 12-month price target is $33.00; the article reports no estimate revisions in the last 30 days. Confirmed

Evidence

• Original source link unavailable